Hengrui Medicine's new generation of PARP inhibitor fluzoparib (Irei®) is included in the new version of the National Medical Insurance Catalogue in 2021

On December 3, 2021, the National Medical Insurance Administration and the Ministry of Human Resources and Social Security officially announced the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2021)"

Source: National Medical Security Administration official website

Ovarian cancer is one of the common malignant tumors in women, and 70% of ovarian cancers are at an advanced stage when they are discovered

In recent years, many studies have shown that PARP inhibitors for platinum-sensitive recurrent ovarian cancer can effectively delay the recurrence of ovarian cancer and improve the overall survival of patients

Maintenance treatment with PARP inhibitors needs to last for 2-3 years.

Fluzoparib, which has entered the new version of the National Medical Insurance Catalogue this time, is a new type of Chinese original PARP inhibitor

At present, the FZOCUS-1 study exploring fluzoparib combined with apatinib for maintenance treatment of advanced ovarian cancer after first-line platinum-containing chemotherapy is underway

Reference materials:

[1] Gao Qinglei et al.

[2] "Progress in Standardized Surgical Treatment of Ovarian Cancer" Yao Xin

[3] "[Fluoride comes to the top, another great achievement] Ovarian Cancer Frontier Forum and Fluzoparibum Sensitive Recurrence Maintenance Therapy Indications Market Meeting Successfully Held" China Medical Tribune Oncology Today

[4] "Chinese Expert Consensus on the Management of Adverse Reactions of PARP Inhibitors (2021 Edition)"

[5] Official Weibo of Hengrui Pharmaceuticals: "New Breakthrough! The second indication of Hengrui Pharmaceutical's innovative drug fluzoparib was approved for marketing.